Kymera Therapeutics Inc., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ending June 30, 2025. The company experienced a net loss of $76.6 million, an increase from the $42.1 million net loss reported in the same period of 2024. Collaboration revenues for the second quarter of 2025 were $11.5 million, down from $25.7 million in the second quarter of 2024, with revenues primarily attributed to the company's collaboration with Sanofi. Kymera ended July 2025 with approximately $1 billion in cash, cash equivalents, and investments, following a $250 million underwritten equity offering and an upfront payment from a strategic partnership with Gilead. This financial position is expected to provide the company with a cash runway into the second half of 2028. Significant corporate updates include the positive Phase 1 results for KT-621 (STAT6) surpassing target product profiles, with plans to report further data from a Phase 1b trial in atopic dermatitis patients by the fourth quarter of 2025. Doses for KT-621 Phase 2b trials in atopic dermatitis and asthma are on track to begin in the fourth quarter of 2025 and the first quarter of 2026, respectively. Additionally, the company's KT-579 (IRF5) is progressing with IND-enabling studies, with a Phase 1 clinical trial expected to start in early 2026.